Skip to main content

Advertisement

SpringerLink
Log in

Clinical implications of ERβ methylation on sporadic breast cancers in Chinese women

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Estrogens play a key role in the genesis and progression of breast cancer, activating two estrogen receptors, alpha and beta (ERα and ERβ). We have previously observed that ERα methylation occurs in high frequency and may be one of the mechanisms of ERα expression silence in a subset of Chinese sporadic breast cancers. However, the ERβ promoter methylation status and the relationship between clinicopathological characteristics and ERβ methylation in sporadic breast cancer are still unknown, especially in Chinese women. This study acted to determine the methylation status of the ERβ promoter and its correlation with clinicopathological features of sporadic breast cancers in Chinese women, and lay a foundation for the management of breast cancer. In total, 178 cases with sporadic breast cancers were enrolled in the study. ERβ methylation was determined using a methylation-specific polymerase chain reaction (MSP). In general, ERβ promoter methylation was found in 44.9% (80/178) of breast tumor samples, significantly higher than the benign breast hyperplasia (44.9% vs. 14.3%, X 2 = 4.986, P = 0.026). A total of 58% (40/69) of ERβ-negative tumors got methylation compared with 36.7% (40/109) of ERβ-positive cases being methylated (X 2 = 7.728, P = 0.005). The levels of ERβ protein expression diminished with the frequency of ERβ methylation (r = −0.249, P < 0.0001). In addition, we observed a strong correlation between ERα promoter and ERβ promoter methylation (odds ratio 2.054, 95% confidence interval 1.086–3.886, P = 0.026), and the triple-negative tumors showed a significantly higher methylation rate of ERβ. This study presents, for what we believe to be the first time, that ERβ methylation is also a frequent event in breast cancer and maybe also one of the mechanisms of ERβ expression silence in a subset of Chinese sporadic breast cancers. Epigenetic alteration of the ERβ gene may play an important role in the pathogenesis of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Yang L, Parkin DM, Ferlay J, Li L, Chen YE. stimates of cancer incidencein China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev. 2005;14:243–50.

    Article  PubMed  Google Scholar 

  2. Allred DC. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol. 2010;23:52–9.

    Article  Google Scholar 

  3. Mosselman S, Polman J, Dijkema R. ERβ: identification and characterisation of a novel human estrogen receptor. FEBS Lett. 1996;392:49–53.

    Article  PubMed  CAS  Google Scholar 

  4. Jensen EV, Jacobson HI, Walf AA, et al. Estrogen action: a historic perspective on the implications of considering alternative approaches. Physiol Behav. 2010;99:151–62.

    Article  PubMed  CAS  Google Scholar 

  5. Bardin A, Boulle N, Lazennec G, et al. Loss of ER beta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer. 2004;11:537–51.

    Article  PubMed  CAS  Google Scholar 

  6. Fox EM, Davis RJ, Shupnik MA. ERbeta in breast cancer–onlooker, passive player, or active protector? Steroids. 2008;73:1039–51.

    Article  PubMed  CAS  Google Scholar 

  7. Roger P, Sahla ME, Mäkelä S, et al. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 2001;61:2537–41.

    PubMed  CAS  Google Scholar 

  8. Swedenborg E, Power KA, Cai W, et al. Regulation of estrogen receptor beta activity and implications in health and disease. Cell Mol Life Sci. 2009;66:3873–94.

    Article  PubMed  CAS  Google Scholar 

  9. Xu X, Gammon MD, Zhang Y, et al. Gene promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat. 2010;121:685–92.

    Article  PubMed  CAS  Google Scholar 

  10. Li LC, Yeh CC, Nojima D, et al. Cloning and characterization of human estrogen receptor beta promoter. Biochem Biophys Res Commun. 2000;275:682–9.

    Article  PubMed  CAS  Google Scholar 

  11. Zhao L, Wang L, Jin F, et al. Silencing of estrogen receptor alpha (ERalpha) gene by promoter hypermethylation is a frequent event in Chinese women with sporadic breast cancer. Breast Cancer Res Treat. 2009;117:253–9.

    Article  PubMed  CAS  Google Scholar 

  12. Herman JG, Graff JR, Myohanen S, et al. Methylation- specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821–6.

    Article  PubMed  CAS  Google Scholar 

  13. Sasaki M, Tanaka Y, Perinchery G, et al. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst. 2002;94:384–90.

    Article  PubMed  CAS  Google Scholar 

  14. Skliris GP, Parkes AT, Limer JL, et al. Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol. 2002;197:155–252.

    Article  PubMed  CAS  Google Scholar 

  15. Speirs V, Skliris GP, Burdall SE, et al. Distinct expression patterns of ERα and ERβ in normal human mammary gland. J Clin Pathol. 2002;55:371–4.

    Article  PubMed  CAS  Google Scholar 

  16. Allred DC, Harvey JM, Berado M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155–68.

    PubMed  CAS  Google Scholar 

  17. Rody A, Holtrich U, Solbach C, et al. Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer. 2005;12:903–16.

    Article  PubMed  CAS  Google Scholar 

  18. Kim SJ, Kim TW, Lee SY, et al. CpG methylation of the ERalpha and ERbeta genes in breast cancer. Int J Mol Med. 2004;14:289–93.

    PubMed  CAS  Google Scholar 

  19. Walton TJ, Li G, Seth R, et al. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate. 2008;68:210–22.

    Article  PubMed  CAS  Google Scholar 

  20. Al-Nakhle H, Burns PA, Cummings M, et al. Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer. Cancer Res. 2010;70:4778–84.

    Article  PubMed  CAS  Google Scholar 

  21. Chen GG, Zeng Q, Tse GM. Estrogen and its receptors in cancer. Med Res Rev. 2008;28:954–74.

    Article  PubMed  CAS  Google Scholar 

  22. Marotti JD, Collins LC, Hu R, et al. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol. 2010;23:197–204.

    Article  PubMed  CAS  Google Scholar 

  23. Mehrotra J, Ganpat MM, Kanaan Y, et al. Estrogen receptor/progesterone receptor negative breast cancers of young African-American women havea higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res. 2004;10:2052–7.

    Article  PubMed  CAS  Google Scholar 

  24. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 2004;36:417–22.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We are very grateful to Dr. Desheng Huang from the Department of Mathematics, College of Basic Medical Sciences, China Medical University for statistical analysis. This work was supported by grants from National Natural Science Foundation of China (No 30873097 and No 30973559), and this study was also supported by the science and technology department of Liao ning province (No 2010225001).

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Pharmacology, China Medical University, Shenyang, 110001, Liaoning, People’s Republic of China

    Lin Zhao, Zhaojin Yu, Yunan Li, Xiaoyan Wen, Lin Wang, Jie Ren, Miao He, Xuefeng Bai, Mingli Sun & Minjie Wei

  2. Department of Surgical Oncology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, Liaoning, People’s Republic of China

    Caigang Liu & Feng Jin

  3. Department of General Surgery, The First Affiliated Hospital of China Medical University, Shenyang, 110001, Liaoning, People’s Republic of China

    Wenfeng Ma

  4. Department of Pathology, China Medical University, Shenyang, 110001, Liaoning, People’s Republic of China

    Xiaoyi Mi & Enhua Wang

  5. Institute of Pathophysiology, China Medical University, Shenyang, 110001, Liaoning, People’s Republic of China

    Zhihong Zheng, Xiaoyi Mi, Enhua Wang & Minjie Wei

  6. Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, 60637-1463, USA

    Olufunmilayo I. Olopade

Authors
  1. Lin Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhaojin Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yunan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaoyan Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wenfeng Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jie Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Caigang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Miao He
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xuefeng Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mingli Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Zhihong Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Xiaoyi Mi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Enhua Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Olufunmilayo I. Olopade
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Feng Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Minjie Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Feng Jin or Minjie Wei.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhao, L., Yu, Z., Li, Y. et al. Clinical implications of ERβ methylation on sporadic breast cancers in Chinese women. Med Oncol 29, 1569–1575 (2012). https://doi.org/10.1007/s12032-011-0107-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-0107-6

Keywords

Search

Navigation